A thread on the most relevant part of the chat on tolerance induction in HLA-matched transplant with donor hematopoietic stem cells (MDR-101). Thread by Akshaya Jayachandran.
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
ASIs Advance: NephJC Shorts on BaxHTN
In ESRD is spironolactone an overACHIEVEr?
NephJC Shorts: The end of the Fluid Wars?
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
NephJC Shorts: BedMed and Chronotherapy
Ensayo STAMP: ¿Tacrolimus o Micofenolato en el síndrome nefrótico pediátrico?
El síndrome nefrótico en niños puede implicar recaídas frecuentes, alta carga de esteroides y decisiones terapéuticas difíciles. Entonces, ¿cuál mantiene mejor la remisión: tacrolimus o micofenolato de mofetilo?
Revisa el VA y únete a la discusión en #NephJC
The STAMP Trial VA: Who Gets the Approval—TAC or MMF in Pediatric Nephrotic Syndrome?
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
TAC or MMF—what works better in pediatric nephrotic syndrome?
Nephrotic syndrome in children, especially those with frequent relapses or steroid dependence, remains a therapeutic challenge. The STAMP trial compared tacrolimus and mycophenolate mofetil to help guide treatment decisions.
STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Double Trouble: ddAVP and the Bleeding Biopsy
REGENCY: A B-Cell Super Destroyer in Lupus
Pain Coping Skills Training in Diaysis
Can we train to deal with the pain? HOPE trial shows us that non-pharmacological intervention can be an option. Visual abstract by Cristina Popa
